Background information. Duchenne muscular dystrophy is a disease characterized by progressive and irreversible muscle degeneration for which there is no therapy. HUCB (human umbilical cord blood) has been considered as an important source of haematopoietic and mesenchymal stem cells, each having been shown to differentiate into distinct cell types. However, it remains unclear if these cells are able to differentiate into muscle cells.
Introduction DMD (Duchenne muscular dystrophy), a severe form of muscular dystrophy, is caused by deficiency in dystrophin, a component of the dystrophin-associated are dystrophin negative (Collins and Morgan, 2003) . Animal models are valuable resources for studying the pathogenesis of diseases and for pre-clinical trials. The mdx mouse has only a mild phenotype (Pastoret and Sebille, 1995) , most likely due to the high regenerative capacity of mouse muscle. However, much of what is known about the molecular biology of dystrophin, the dystrophin-associated proteins and their interactions (Durbeej and Campbell, 2002) , as well as the role of inflammation in regeneration and fibrosis (Spencer and Tidball, 2001) , came from studies in this mouse model.
Regarding restoration of dystrophin expression, studies in mice have demonstrated that haematopoietic stem cells can contribute to skeletal muscle regeneration. In normal and mdx mice, BM (bone marrow)-derived cells were shown to participate in skeletal muscle repair after induced damage (Ferrari et al, 1998; Gussoni et al., 1999; Corbel et al., 2003) . However, the clinical usefulness of haematopoietic cell transplantation for muscular dystrophies, such as DMD (Cossu and Sampaolesi, 2004) , depends on the expansion, homing and myogenic differentiation of transplanted cells.
More recently, HUCB (human umbilical cord blood) has been investigated as an alternative source to BM for cell transplantation and therapy, because of its haematopoietic and non-haematopoietic (mesenchymal) components (Erices et al., 2000) . In contrast with BM aspiration, HUCB is obtained by a simple, safe and painless procedure after birth. Some studies suggest that HUCB-derived cells can differentiate both in vitro and in vivo into non-haematopoietic cells, such as neurons or glia (Sanchez-Ramos et al., 2001; Zigova et al., 2002) . Also, studies have shown that subpopulations of HUCB cells can differentiate into hepatic, endothelial or muscle cells (Ishikawa et al., 2003; Pesce et al., 2003) .
It is well established that muscle function requires the co-ordinated development of several tissues, such as bone, cartilage and tendon, but there is little information concerning the factors that induce proliferation and differentiation of cells into myotubes/muscle fibres. In the present study we have investigated whether HUCB stem cells could undergo myogenesis when cultured in low-serum conditions, muscle-conditioned medium or with muscle cells in vitro. We also evaluated if, after local administration, these GFP (green fluorescent protein)-tagged cells were able to engraft on to dystrophic mdx muscle and fuse to become part of the myofibres, thereby allowing expression of dystrophin in the mdx host. The presence of human dystrophin in GFPpositive cells and the expression of genes involved in the myogenic programme suggest the successful differentiation of HUCB-derived cells.
Results

HUCB harvest, cell preparation and morphological analysis
MNCs (mononucleated cells) were obtained from HUCB and plated in culture flasks. After 5 days of culture, non-adherent (floating) cells were transferred into another flask. These cells presented high proliferation rates early in the isolation process; however, cell death was a common feature immediately after isolation (data not shown). The adherent cells were small and round-shaped ( Figure 1A) . Most of the cells maintained a round shape, although we did detect some well-defined subpopulations, including a group of cells with a more spindle-shaped appearance. The more elongated cells started to appear among rounded cells between 10 and 18 days of culture ( Figure 1B ). These cells became fibroblast-like cells. Following 3 or 4 passages of culture, the adherent cells became a population consisting mainly of fibroblast-like cells and grew to confluency ( Figure 1C ).
Cell characterization by flow cytometry
Flow cytometry was used to evaluate expression of the haematopoietic and mesenchymal cell markers: CD34, CD45, CD117, CD29 and SH2. Floating cells expressed CD45 and CD34 markers (Figures 2A and  2B ). Since CD34 positive cells represent 0.1-0.5% of the MNC fraction of HUCB, this population was only efficiently detected after immunomagnetic selection using specific antibodies. Adherent cells expressed neither the haematopoietic lineage marker CD45 nor CD34 (Figures 2F and 2G) , suggesting that adherent cells were depleted of haematopoietic precursors during culturing. However, they expressed CD29 and SH2 (CD105), which are well-known mesenchymal stem cell-specific markers (Figures 2H and 2I) . A small percentage of haematopoietic cells expressed the CD117 stem cell marker ( Figure 2E ) and this antigen was almost absent in adherent cells (Figure 2J) . Flow cytometry studies revealed that the MNCs maintained the same general profile at each time point analysed. Data indicated that adherent cells derived from HUCB display a mesenchymal stem cell phenotype.
In vitro myogenic differentiation and co-culture experiments
Floating and adherent MNC were placed into DM (differentiation medium) or CM (conditioned medium), and cultured for an additional 30 days. Following this period, cells were screened for the presence of muscle proteins, such as desmin and dystrophin. Differentiation efficiency was also verified by the occurrence of fusion of MNCs to form myotubes. Results showed that, in medium with a low concentration of bovine serum or CM, MNCs (both haematopoietic and adherent populations) did not fuse into multinucleated dystrophin-positive myotubes, but remained as MNCs ( Figure 3A) , and only few cells expressed the myogenic marker desmin ( Figure 3B ). On the other hand, under these conditions, pre-confluent myoblasts were able to fuse and form myotubes, as shown in Figures 3(C) and 3(D).
To test whether myogenesis (and dystrophin expression) could be induced by co-culture of haematopoietic or adherent cells with human myoblasts from healthy or DMD donors, we first transduced these cells with a lentiviral vector, which expressed the eGFP (enhanced GFP) protein in more than 70% of the cell population, as detected by flow cytometry and fluorescence microscopy (data not shown). Transduced cells did not fuse to form GFP-positive myotubes, even when co-cultured with human myoblasts.
RT-PCR (reverse transcription PCR) analysis of myogenic markers expression
We performed RT-PCR analysis to investigate whether the CD34 + (used as a representative haematopoietic stem cell) and mesenchymal cells obtained from HUCB were capable of expressing myogenic markers and undergo myogenic differentiation in vitro. RT-PCR with specific oligonucleotides for human myogenin, MYF5 (myogenic factor 5), MRF4 (myogenic regulatory factor 4) and MyoD (myogenic determination factor) revealed the appearance of transcripts for these genes in adherent MNCs after 15 days of culturing in DM or CM (Figure 4 ). This population was positive for PAX-7 and M-cadherin expression. PAX-7 expression was also verified in CD34 + cells cultured in DM. To study the ability of MNCs to differentiate into muscle cells in vivo, we analysed these myogenic mRNAs in the quadriceps muscle of injected mdx mice. Human M-cadherin, Removal of FBS and supplementation of the medium with 10% horse serum (DM) allowed human myoblasts to fuse and form myotubes (C). Nuclei of myotubes were stained by DAPI (4 ,6-diamidino-2-phenylindole) (D). Phasecontrast light and fluorescence microscopy images were acquired every week of at least three random fields.
MRF4 and PAX7 were detected in the recipient mdx muscles (data not shown). No human transcripts were detected in the muscles of control mdx or in contralateral muscle of the same animal. RT-PCR in cell cultures obtained from mdx explants provided similar results, with the expression of M-cadherin, myogenin and PAX-7. Dystrophin mRNA was barely detectable, even in long-term cultures (90 days).
Explant cultures of injected muscles
Following total MNC transplantation in mdx mice, we were not able to estimate the percentage of cells expressing GFP in the muscle biopsy; however, the majority of MNCs isolated from muscle explants were GFP-positive. This population consisted of fibroblast-like cells, similar to the ones obtained in the separation process. These cells were then analysed for their ability to spontaneously fuse and form myotubes in vitro ( Figures 5A-5D ) or when switched into DM. Co-culture of GFP-labelled MNCs with mdx muscle-biopsy fragments also allowed cell fusion to form extended structures that resemble multinucleated myotubes. Cells obtained from the contralateral muscles or non-injected mice did not show any GFP fluorescent signals, suggesting that the transplanted cells were mainly restricted to the local area of injection.
In vitro and in vivo dystrophin expression: myogenic markers detection by immunostaining
Dystrophin expression in cell (co)cultures was evaluated by immunostaining, Western blotting and RT-PCR. This protein was detected in control myoblasts cultured for 30 days, but not in MNCs (haematopoietic or mesenchymal populations) cultured in PM (proliferation medium), DM or with muscle cells for the same time ( Figures 6A-6C ).
To evaluate the in vivo dystrophin expression, and to determine whether HUCB cells survive and undergo myogenic differentiation within the mdx recipients, we immunostained muscle samples with three different antibodies. Control experiments revealed that the anti-dystrophin antibodies DYS1 and DYS2 were not suitable to evaluate dystrophin expression in transplanted mdx muscle. These antibodies are produced in mouse, and the anti-mouse secondary antibodies strongly reacted with proteins in the mouse tissue. On the other hand, MANEX1216E did not detect dystrophin in mouse muscle ( Figures 7A and 7B ). Examination of frozen sections of injected muscles showed a restricted and small number of human dystrophinpositive myofibres in comparison with the control animals and contra-lateral muscles of the same animal ( Figure 7C ). In addition, we could not correlate the improvement of characteristics of dystrophic muscles, such as the presence of central nuclei and degeneration/regeneration areas, with the MNC transplantation. By Western blotting (Figure 8) , it was possible to detect only degradation products of dystrophin in mdx muscle collected before (Figure 8 , lane 4) and 45 days after MNC transplantation (Figure 8, lane 6) . However, myotube-like structures obtained after culturing (approx. 90 days) of cells from mdx explants in PM, DM or in the presence of mdx muscle fragments expressed the 420 and 390 kDa dystrophin bands, amongst others products (Figure 8 , lane 9). In agreement with this result, immunostaining of these multinucleated structures revealed the presence of dystrophin ( Figure 6D ), as well of desmin and α-actinin (Figures 6E and 6F respectively).
Figure 5 Cell cultures of mdx mice quadriceps muscles injected with HUCB cells
The quadriceps muscle, previously injected with human MNCs, was excised from mdx mice and dissociated in trypsin. After 5 to 7 days in PM, adherent cells were removed by trypsinization and plated into another culture flask. After cells achieved the confluence, PM was replaced by DM. These cells were able to fuse and form multinucleated structures (A and B; light and fluorescence respectively). (C) and (D) show the same multinucleated structures, indicated by arrows, in higher magnification.
Discussion
Muscular dystrophies are recognized as difficult diseases to treat, mainly due to the fact that skeletal muscle is the most abundant tissue of the body and composed of multinucleated fibres. However, it is not known how many nuclei have to be repaired in order to restore muscle function.
A study (Partridge et al., 1989) involving the injection of muscle cells (myoblasts) into mdx mice resulted in the conversion of muscles fibres from dystrophinnegative to dystrophin-positive. However, several similar clinical trials failed for different reasons; the most important of which were the poor survival and the very limited migratory capacity of injected donor cells, together with the immune response of the patient. More recent pre-clinical studies have shown that the major problem still faced by this approach is the lack of dispersion of donor cells, which remain in the area of injection. This might be overcome by using blood stem cells. The possible systemic delivery of circulating cells was the obvious choice over satellite cells that cannot cross the endothelial layer.
Experimental stem cell therapy for primary muscular dystrophies and heart attack with BM-derived stem cells has been attempted by several groups (Ferrari et al., 1998; Itescu et al., 2003; Cossu and Sampaolesi, 2004) . According to Ferrari et al. (1998) , muscle repair by BM-derived cells seemed to be an insignificant phenomenon, representing less than 0.5% of the regenerated fibres in muscles of the transplanted mice. Other groups have shown that in mdx mice transplanted with the BM or enriched haematopoietic stem cell fractions of syngeneic C57Bl/10 mice, there were a small number of dystrophinpositive fibres containing genetically marked (Y chromosome) donor nuclei after transplantation (Bittner et al., 1999; Gussoni et al., 1999) . In addition to low abundance, failure to grow extensively in vitro Figure 6 Myogenic markers detection by immunostaining Expression of muscle proteins in cultured cells was evaluated by immunostaining using antibodies (1:100) against desmin, α-actinin or dystrophin. Cy3-or FITC-conjugated anti-mouse or anti-rabbit antibodies (1:100) were used as secondary antibodies. Samples were analysed under fluorescence microscopy using appropriate filters. Dystrophin detection in control myoblasts (A). MNCs, isolated from mdx muscle explants, were able to fuse and form multinucleated structures (myotubes) that expressed dystrophin (D), α-actinin (E) and desmin (F) 
Figure 7 In vivo dystrophin analysis by immunofluorescence
The quadriceps muscle from mdx mice was collected 45 days post-transplantation. Immunostaining was performed in 10 µm muscle sections using the anti-dystrophin antibody MANEX1216E (1:100). Cy3-conjugated anti-mouse (1:100) was used as secondary antibodies. The antibody bound specifically to human dystrophin (A), but it did not detect dystrophin in mouse muscle (B). Representative field showing a small number of fibres with human dystrophin in injected mdx (C).
and a low differentiation potency towards nonhaematopoietic cells suggest together that the therapeutic potential of BM transplantation for muscular dystrophies is uncertain.
Following the successful transplantation of HUCB cells to treat Fanconi's anaemia (Gluckman et al., 1989) , there has been extensive use of these cells to reconstitute the haematopoietic system in both humans
Figure 8 In vivo and in vitro dystrophin detection by Western blotting
The dystrophin doublet (420 and 390 kDa) was detected in human muscle cells (lane 1), but not in muscle cells from a DMD patient (lane 2). Muscle biopsies from C57BL were dystrophin-positive (lane 3). Only low-molecular-mass species of dystrophin were detected in samples from mdx quadriceps muscle collected before transplantation (lane 4) or in injected mdx muscle collected 45 days post-transplantation (lane 6). mdx contralateral muscle collected 45 days before transplantation (lane 5; protein amount was at approximately one-fifth of the total present in the sample of injected muscle). Cells obtained from mdx muscle explants and cultured in the presence of mdx muscle fragments for 60 days did not express dystrophin (lane 7), whereas this protein could be detected in these cells after culture for 90 days (lane 8). (Rocha et al., 2000) and mice (Wang et al., 1997) . Other studies have suggested that HUCB-derived cells (both haematopoietic and mesenchymal populations) can differentiate into non-haematopoietic cells such as myoblasts (Erices et al., 2000; Gang et al., 2004) , but the factors required for muscle differentiation are not well understood.
We have demonstrated that haematopoietic or mesenchymal cells from HUCB were not able to differentiate and fuse into myotubes when cultured with DM, CM or directly with muscle cells. This result indicates that chemical factors or cell-to-cell contact were not sufficient, in this case, to induce the full differentiation programme in vitro. In these conditions, a small number of these cells expressed the myogenic marker desmin, which could suggest a certain degree of myogenic commitment.
Expression analysis by RT-PCR of some myogenic markers in adherent (mesenchymal) cells cultured in DM revealed the presence of transcripts for PAX-7 and M-cadherin, two well-known markers of satellite cells and myoblasts (Irintchev et al., 1994; Seale et al., 2000) . Satellite cells constitute a population of mononucleated precursors that retain the capacity to generate new fibres in adult muscle. In response to increased workload and to repair or regenerate muscle fibres, they become activated, proliferate and express these myogenic markers. With regards to the pattern of gene expression demonstrated in the present study, other studies support the idea that BM-derived cells can reach the site of muscle regeneration and contribute to muscle repair, as well as to replenishment of the satellite cell pool (Corbel et al., 2003; Cossu and Sampaolesi, 2004) .
Mesenchymal cells were also positive for MYF5, MyoD, MRF4 and myogenin when cultured in DM, suggesting that they were induced to undergo myogenesis and that the myogenic potential found after transplantation might reside in this cell population. In fact, skeletal myogenesis is a developmental cascade that involves the regulatory gene MyoD, which is expressed at the early stage of myogenic differentiation, whereas myogenin is expressed later at the time of cell fusion (Edmondson and Olson, 1993) . So, it is tempting to think that once differentiation is triggered either by the binding of soluble molecules to the cell surface or by transcription factors from neighbouring cells or nuclei within the same cytoplasm, the expression of the entire genetic repertoire of a differentiated tissue will follow. However, it is well established from tissue culture studies that, in vitro, skeletal myoblasts differentiate into multinucleated myotubes and express a large number of muscle-specific genes upon depletion of growth factors in the medium (Arnold and Winter, 1998) . In addition, genes encoding sarcomeric proteins, as well as other late-expressing genes in mature muscle fibres in vivo, are not expressed in vitro in the absence of nerve and hormones (Weiss and Leinwand, 1996) . These observations may explain why the myogenic program did not proceed in cultured cells, even when they have expressed MyoD.
To assess the in vivo dystrophin expression and to determine whether HUCB cells went through myogenic differentiation within the mdx recipients we have used GFP-labelled MNCs in transplantation experiments. We could not quantify human donor GFPpositive cells in the muscle of recipient mdx mice. The presence of this protein in GFP-positive muscle cells could provide strong support for the hypothesis that a (sub)population of HUCB cells possesses myogenic potential. Results indicate that MNCs did not significantly contribute to in vivo dystrophin expression, but some dystrophin-positive fibres could be identified by immunostaining. Western blotting showed that only dystrophin degradation products were detected after transplantation, which may reflect the small amount of intact protein in the sample. Using RT-PCR of injected muscles or explants from mdx mice, we showed the expression of human PAX-7, M-cadherin and MyoD. Taken together our results indicate that these cells may participate in muscle regeneration and contribute to the replacement of the pool of satellite cells.
Results with myotube-like structures obtained after culture of GFP-positive cells from mdx explants suggested that they contain nuclei derived from the injected MNCs. They behaved like typical myotubes in vitro and showed the early expression of desmin and α-actinin, whereas dystrophin was only detected in long-term cultures (90 days). The fact that dystrophin was detected by Western blotting in cell cultures, but not in transplanted mdx muscle (45 days pos-transplantation) may result from the time required for dystrophin expression.
It has been demonstrated that some stem cell studies reporting transdifferentiation may indeed reflect a process of fusion of donor stem cells with host cells (Terada et al., 2002; Ying et al., 2002; Wang et al., 2003) , which illustrates the difficultly in verifying that true stem cell transdifferentiation has occurred. Also, it is well established that multinucleated myofibres are formed by fusion of MNCs, and that this fusion event can produce myotubes with nuclei originating from more than one source (Gussoni et al., 1999) .
In summary, our findings showed that the HUCBderived stem cells were capable of acquiring a muscle phenotype when in contact with the in vivo environment, leading to expression of muscle proteins; however, the exact factors that were responsible for activation of the myogenic process of HUCB cells described here remains unclear. On the other hand, the present study raises the possibility that HUCB might ultimately represent a tool for future cell therapy of degenerative disorders of muscle, such as the muscular dystrophies.
Material and methods
HUCB-derived cells harvest and cell preparation
HUCB samples were obtained by a simple, safe and painless procedure after birth following written consent from the mother, as well as approval from the University of Sao Paulo Ethical Committee. The units were stored at 22
• C and blood samples were processed within 24 h of collection. MNCs were isolated by density-gradient centrifugation using Histopaque 1077 ® (Sigma) (400 g for 30 min at room temperature). MNCs were removed from the interphase and washed twice with cold PBS containing 2 mM EDTA. Cells were suspended in PM comprising high-glucose DMEM (Dulbecco's modified Eagle's medium) (Invitrogen Life Technologies), 15% FBS (fetal bovine serum), 100 units/ml penicillin, 100 µg/ml streptomycin and 2 mM glutamine. Cell counting was performed by flow cytometry (Guava Technologies, Hayward, CA, U.S.A.) and cells were plated at a density of 1.0 × 10 6 cells/cm 2 in culture flasks (25 cm 2 ). After 5 days of culture, suspended cells were removed and put into another culture flask. Floating (haematopoietic) cells were cultured in Stem Span containing a cocktail of cytokines (100 ng/ml stem cell factor, 100 ng/ml Flt-3 ligand and 100 ng/ml thrombopoietin, interleukin-3 and interleukin-6) and adherent (mesenchymal) cells were cultured in PM. Cultures were maintained at 37
• C in a humidified atmosphere containing 5% CO 2 and the culture medium was changed every 3 days.
Samples of MNCs were incubated with CD34 monoclonal antibody-conjugated to paramagnetic MicroBeads (CD34 isolation kit; Miltenyi Biotech, Bergisch-Gladbach, Germany), washed and processed through a MACS magnetic separation column (Miltenyi Biotech) to obtain purified CD34 + cells. After selection, an aliquot of the CD34 + cell fraction was analysed for purity by flow cytometry. The myogenic potential of CD34 + cells was also evaluated by RT-PCR.
Cell characterization by flow cytometry
Both floating (haematopoietic) and adherent (mesenchymal) cells were characterized with mouse anti-[human PerCP (peridinin chlorophyll protein)]-conjugated CD34, FITC-conjugated CD45, PE (phycoerythrin)-conjugated CD117 (c-Kit), PE-Cy5-conjugated CD29 monoclonal antibodies (all from BD Biosciences PharMingen, San Diego, CA, U.S.A.). Anti-SH2 (CD105) antibodies were also incubated with cells. A separate sample of cells was treated with equivalent amounts of isotype control antibodies. Propidium iodide was added to exclude nonviable cells from the analysis. Appropriate gating was performed to determine the molecular markers expression via flow cytometry (Guava Technologies).
In vitro myogenic differentiation of HUCB-derived cells
After 5 days in PM, floating and adherent MNCs were placed in DM (high-glucose DMEM, 2% FBS, 10% horse serum, 100 units/ml penicillin, 100 µg/ml streptomycin and 2 mM glutamine) or CM (the medium used to grow human myoblasts for 3 days). Human myoblasts for co-cultures experiments were obtained from biceps muscle biopsies from healthy donors or a patient with DMD carrying a deletion encompassing exons 3 to 37 ( 3-37) of the dystrophin gene. Biopsies were collected after written informed consent and approved by the Ethics Committee of the Department of Genetics and Evolutionary Biology, University of Sao Paulo. Muscle fragments were mechanically dissociated and plated on to bovine-serum-coated plates. After 1 day, fresh DMEM was added to the cultures, and they were maintained in these conditions until cells came out of the explants. Muscle cells were collected by trypsinization and used in the experiments. Some muscle cell cultures were mixed with MNCs (haematopoietic and mesenchymal populations in separate) at a ratio of 1:3. In this case, MNCs were first transduced with a third-generation lentivirus vector expressing eGFP cDNA as a reporter gene (Lois et al., 2002) . Co-cultures were maintained in PM for 3 days and then were switched to DM. Phase-contrast light and fluorescence microscopy images were acquired weekly in at least three random fields. After additional 30 days of culture in the three different conditions, differentiation was evaluated based on the ability of the MNCs to fuse and form multinucleated myotubes. Desmin and dystrophin expression was assessed by immunocytochemistry using specific antibodies against the deleted region in the DMD patient, and by RT-PCR using a specific primer comprising an absent exon in the dystrophin cDNA of the DMD patient.
Animals, immunosuppression and transplantation
Two-month-old male mouse mdx recipients were obtained from the animal facility at the Department of Genetics and Evolutionary Biology, University of Sao Paulo. The protocol was approved by the University Ethics Committee on Research Animal Care. Animal care was in accordance with institutional guidelines of University of Sao Paulo. The animals received a daily dose of 1 mg/kg FK506 (Tacrolimus, Janssen-Cilag, Killorglin, Ireland) intraperitoneally from the day before cell injection until the animals were killed. The mdx mice were divided into two groups (n = 2) for the transplantation experiments (control and treated group). Animals were anaesthetized with ketamine hydrochloride (80 mg/kg) and xylazine (10 mg/kg) before cell injection. Each animal was injected with 1.0 × 10 6 eGFP-transduced MNCs (treated group) or the vehicle only (PBS, control group) into the quadriceps muscle. Animals were analysed at 45 days post-transplantation.
Muscle samples and slide preparation
At 45 days post-transplantation, animals were killed by cervical disruption and the quadriceps muscle was collected from each mouse and frozen in liquid nitrogen. Samples of the contralateral muscles were also collected and used as controls. Slides of 10 µm sections were prepared and stored at −80
• C until further analysis.
Explant cultures of injected muscles
For explant experiments, the quadriceps muscle was excised from mdx mice previously injected with human MNCs and was finely minced in the presence of 0.25% trypsin. Dissociated cells were plated into culture flasks containing 4 ml of PM. After the MNCs had migrated out from the explants (between 5 and 7 days), adherent cells were removed by trypsinization (0.25% trypsin and 2 mM EDTA) and replated at a density of 1.8 × 10 3 cells/cm 2 in 35-mm dishes. This culture medium was changed twice a week. When cells achieved the confluence, PM was replaced by DM. Additionally, cells were cultured in the presence of mdx muscle fragments. Cells were analysed for the presence of dystrophin, desmin and α-actinin by immunostaining and Western blotting or for the expression of myogenic genes by RT-PCR.
Protein detection by immunostaining
Expression of the muscle proteins in cultured cells or in muscle slides was evaluated by immunostaining. Briefly, after fixation with 4% paraformaldeyde, non-specific sites were blocked with PBS containing 2% FBS, and then they were incubated with 1:100 diluted antibodies against desmin (Sigma-Aldrich), α-actinin (Novocastra, Newcastle upon Tyne, U.K.) or dystrophin (DYS1, which bind to rod domain of the protein; DYS2, which bind to the C-terminus; MANEX1216E which specifically react with human dystrophin), and rabbit polyclonal anti-dystrophin antibody (Ab15277; Abcam, Cambridge, U.K.). Cy3-or FITC-conjugated anti-mouse or anti-rabbit (1:100) were used as secondary antibodies (Sigma-Aldrich or CyDye, GE Healthcare). Samples were analysed by fluorescence microscopy using appropriate filters for the fluorophores.
RT-PCR
RT-PCR was used to verify the presence of myogenic mRNA species in cultured cells or muscles from injected mice. Total RNA was extracted by standard Trizol method as indicated by the manufacturer (Invitrogen). First-strand cDNA was prepared with the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen), starting with 2 µg of total RNA and an oligo(dT) 12−18 primer. cDNA amplification of human markers was performed with primers specifically designed in non-homologous regions of human/mouse sequences (MRF4 forward, GATCCCACCGACCCTTCCTGG, and MRF4 reverse, GAG-GCTAGACCTAAGCCACTCGC; Myog forward, GTCTTCC-AAGCCGGGCATCCTTG, and Myog reverse, GAGCTGGGG-CATACACGAGGGG; MyoD forward, CGATATACCAGGT-GCTCTGAGGG, and MyoD reverse, GGGTGGGTTACG-GTTACACCTGC; MYF5 forward, CCAGGCTTATCTATCAT-GTGCTATG, and MYF5 reverse, GTTAAGCATTGCAACAA-GCTACCC; PAX-7 forward, GTACGGCCAGAGTGAGTGC-CTG, and PAX-7 reverse, CTGTTGGAGCCATAGTACGGA-AG; M-cad forward, CCCGTGCGGGTTGGAGTACGG, and M-cad reverse, CACTGGTAGGAGGCAAAGGTGGG; CD34 forward, GACACTGTGGACTTGGTCACCAG, and CD34 reverse, GAGGAGGAAGCCATGGAGATCAG). We also designed a specific primer for dystrophin cDNA amplification, which covers the absent exon in the DMD patient (Ex5 forward, TGAATATTGGAAGTACTGACATCGTA, and Ex6 reverse, CTATGACTATGGATGAGAGCATTCCAA). Reactions were carried out in a PTC-100 TM thermocycler (MJ Research, Watertown, MA, U.S.A.) with the following conditions: 94
• C for 5 min, then 40 cycles at 94
• C for 30 s, 58
• C for 30 s, and 72
• C for 1 min. Final extension was performed at 72
• C for 15 min. DNA was analysed on 2.0% agarose gels and stained with 0.5 µg/ml ethidium bromide. DNA bands were visualized under UV transillumination and images were taken using ImageMaster VDS equipment (GE Healthcare). β-Actin mRNA amplification was used to standardize the amount of cDNA in each sample.
Western blotting
For Western blotting experiments, muscle biopsies from noninjected or injected mdx mice were homogenized in 25 mM Hepes, pH 7.4, containing 0.1% Triton X-100, 0.1% SDS and a cocktail of protease inhibitors (100 µM PMSF, 10 µg/ml leupeptin, 10 µg/ml pepstatin and 5 mM EDTA). Homogenates were centrifuged at 12 000 g for 10 min and the supernatant was collected. Samples from cell cultures were first washed twice with cold PBS and cells were lysed with the same buffer with the protease inhibitors. All samples were boiled for 7 min. Extracted proteins (approx. 100 µg) were separated by PAGE (6% gel) and were electrotransferred on to nitrocellulose membranes (GE Healthcare) for 48 min at 0.35 A at 4
• C. Membranes were blocked with 5% non-fat milk in PBS-T (PBS/0.1% Tween 20) for 2 h and subsequently incubated with monoclonal antibodies directed against the dystrophin rod domain (DYS1). After an overnight period of incubation at 4
• C with the primary antibody, membranes were washed three times with PBS-T for 10 min. The horseradish-peroxidase-conjugated anti-(goat IgG) secondary antibody was incubated at 1:5000 for 1 h at room temperature. Bound proteins were visualized using a commercially available chemiluminescence kit (ECL, GE Healthcare) according to the manufacturer's instructions. Membranes were then exposed to autoradiography films (Kodak, Rochester, New York, U.S.A.), which were developed and scanned.
